Saturday 17 October 2026 Export PRPO’s income statement to Excel — free account

Precipio, Inc.

Precipio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.0 million, up 29.8% from fiscal 2024. In the quarter to June 2026, revenue grew 24.2%, EPS fell 340.0%, free cash flow grew 79.6% and total debt rose 47.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

21.38 1.16 −5.15%

Follow PRPO

Alert me

Market cap: $40.4M
P/E: 0.0×
Fwd P/E: 15.4×
Dividend yield: —
F-score: 6/9
Altman Z: −2.40
Beneish M: −1.62
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.00

Total sells 0.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	1	—	—	1	—	—	—	—	—	—
Sell	—	—	—	—	—	—	2	—	—	—	—	—

Insider Ownership 12.16%

Capital & Financial Ratios $m

Market Cap 40.35

Revenue 27.20

Net Income (1.21)

Free Cash Flow 0.79

Net Debt (2.10)

Current Ratio 1.77

Debt/Equity 0.07

P/E ratio 0.00

Fwd P/E 15.40

P/S ratio 1.41

P/B ratio 2.59

Past 5Y EPS Growth —

This Y EPS Growth 106.24%

Next Y EPS Growth 106.24%

Next Y revenue growth 71.74%

Next 5Y EPS Growth 20.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 26.24%

10-year low 10-year high

P/B against its own 10 years 84.12%

10-year low 10-year high

EV/Sales against its own 10 years 25.95%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2	1	3	3
Receivables	1	1	2	2
Inventory	0	1	1	1
Other	0	1	0	0
	4	3	6	7

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	0	0	0	0
Other	—	—	—	—
	3	4	4	4

Compound Annual Growth %

	10y	5y	3y
Sales	28.70%	31.60%	36.71%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.56%	(3.82%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	7	7	—	—	—
’25	5	6	7	7	24
’24	3	4	5	5	19
’23	3	4	5	4	15
’22	2	2	2	2	9
’21	2	2	2	2	9
’20	1	1	2	2	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	1	—	—	—
’25	0	0	0	0	1
’24	(1)	1	0	1	0
’23	(2)	(1)	(1)	0	(4)
’22	(2)	(2)	(2)	(1)	(8)
’21	(1)	(2)	(2)	(1)	(7)
’20	(2)	(2)	(2)	(1)	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	1	—	—	—
’25	0	0	0	0	0
’24	(1)	0	0	1	0
’23	(2)	(1)	(1)	0	(4)
’22	(2)	(2)	(2)	(2)	(8)
’21	(1)	(2)	(2)	(1)	(7)
’20	(2)	(2)	(2)	(1)	(8)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.81)	(0.12)	—	—	—
’25	(0.59)	0.05	(0.05)	0.34	(0.23)
’24	(1.46)	(0.83)	(0.42)	(0.23)	(2.93)
’23	(2.60)	(1.80)	(1.04)	0.88	(4.51)
’22	(4.00)	(1.80)	(2.80)	(2.00)	(10.80)
’21	(1.60)	(2.80)	(1.60)	(1.80)	(8.00)
’20	(15.60)	(4.00)	(4.20)	2.84	(17.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1,359.01	297.00	45.00	33.00	11.00	31.20	9.40	4.75	4.31	3.90	Analyst estimates 2026–2028 Powerpack
	High	10,350.05	14,310.07	525.00	216.00	160.00	183.60	35.40	20.48	7.30	28.50
People
People	Employees	19	33	45	51	57	56	56	57	60	71
	Revenue/emp, $m	0.09	0.05	0.06	0.06	0.11	0.16	0.17	0.27	0.31	0.34
Income, $m
Income, $m	Revenue	2	2	3	3	6	9	9	15	19	24
	Gross margin, %	43.70	16.95	7.86	7.00	18.88	27.03	26.67	39.60	40.79	44.52
	EBT	(2)	(21)	(16)	(13)	(11)	(9)	(12)	(6)	(4)	0
	EBT margin, %	(129.25)	(1,201.04)	(557.72)	(425.74)	(173.97)	(96.25)	(129.39)	(38.51)	(23.15)	(1.51)
	Net income	(2)	(21)	(16)	(13)	(11)	(9)	(12)	(6)	(4)	0
	Depreciation	0	12	6	3	2	1	2	2	2	2
Per share, $
Per share, $	Revenue	1,230.71	111.16	39.72	10.98	7.39	8.39	8.27	11.71	12.65	14.98
	Earnings	(2,976.96)	(710.80)	(275.80)	(46.60)	(17.00)	(8.00)	(10.80)	(4.51)	(2.93)	(0.23)
	Cash flow	(685.00)	(431.61)	(93.68)	(32.10)	(9.02)	(6.23)	(6.79)	(2.74)	0.30	0.43
	Capex	0.00	(9.23)	(1.35)	(0.19)	(0.12)	(0.65)	(0.24)	(0.10)	(0.15)	(0.20)
	Free cash flow	(685.00)	(440.84)	(95.02)	(32.29)	(9.14)	(6.88)	(7.03)	(2.84)	0.15	0.22
	Book value	(4,614.29)	840.32	84.92	46.37	17.19	23.32	14.39	11.12	8.25	9.07
	Shares, m	0	0	0	0	1	1	1	1	1	2
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	2.14	3.10	1.16	3.73	5.60	3.77	1.50	0.56	0.44	1.53
	P/B	0.00	0.41	0.54	0.88	2.41	1.35	0.86	0.59	0.67	2.53
	EV/Sales	4.83	4.91	2.79	3.71	5.35	2.49	1.18	0.48	0.40	1.46
	EV/FCF	(7.10)	(1.23)	(1.17)	(1.26)	(4.33)	(3.03)	(1.39)	(1.98)	44.62	97.67
Cash, $m
Cash, $m	Operating cash flow	(1)	(7)	(7)	(9)	(7)	(7)	(8)	(4)	0	1
	Capex	—	0	0	0	0	(1)	0	0	0	0
	Free cash flow	(1)	(7)	(7)	(9)	(8)	(7)	(8)	(4)	0	0
Balance, $m
Balance, $m	Working capital	(2)	(8)	(12)	(2)	0	9	1	1	(1)	2
	Total debt	5	4	5	1	1	0	0	0	1	1
	Net debt	5	3	5	0	(2)	(11)	(3)	(1)	(1)	(2)
	Shareholders’ equity	(6)	13	6	13	14	25	16	14	12	15
Returns, %
Returns, %	ROA	(144.29)	(236.35)	(81.51)	(64.42)	(69.46)	(33.35)	(46.99)	(29.56)	(24.45)	(1.89)
	ROIC	0.00	(60.09)	(80.58)	(52.30)	(45.25)	(45.24)	(59.78)	(35.85)	(23.06)	(5.90)
	ROE	42.24	(1,012.93)	(208.02)	(137.03)	(102.09)	(44.01)	(59.57)	(38.01)	(32.35)	(2.72)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BNR Burning Rock Biotech Limited Sponsored ADR	$137.1M	— (loss-making)	11.1×	−4.22% (below 0%: shrinking)	n/m	+46.01% (above 0%: growing)	72.58%	(13.36%)	Compare
MDXHF MedX Health Corp.	$103.2M	— (loss-making)	— (loss-making)	+33.59% (above 0%: growing)	n/m	+41.60% (above 0%: growing)	37.19%	(1,027.95%)	Compare
IMDX Insight Molecular Diagnostics Inc.	$100.1M	— (loss-making)	— (loss-making)	−53.86% (below 0%: shrinking)	n/m	−54.02% (below 0%: shrinking)	65.69%	(4,770.71%)	Compare
QUCY Quantum Cyber N.V	$95.1M	— (loss-making)	— (loss-making)	+11.12% (above 0%: growing)	n/m	+26.73% (above 0%: growing)	62.71%	0.00%	Compare
MDXH MDxHealth SA	$57.6M	— (loss-making)	— (loss-making)	+12.01% (above 0%: growing)	n/m	−200.20% (below 0%: shrinking)	65.75%	(18.74%)	Compare
MBAI MBody AI Ltd.	$47.4M	— (loss-making)	—	—	n/m	+122.08% (above 0%: growing)	0.00%	0.00%	Compare
PRPO Precipio, Inc.	$40.4M	— (loss-making)	15.4×	+24.18% (above 0%: growing)	n/m	+79.59% (above 0%: growing)	44.67%	(8.53%)
PMD Psychemedics Corporation	$15.7M	— (loss-making)	— (loss-making)	−11.46% (below 0%: shrinking)	n/m	+57.45% (above 0%: growing)	31.37%	3.80%	Compare
ADVB Advanced Biomed Inc.	$8.1M	0.8×	—	—	n/m	−101.33% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$76.3M	—	—	+3.45%	—	+34.17%	62.71%	(6.68%)

All 52 Diagnostics & Research stocks →

Precipio, Inc. (PRPO) key facts

Strength: Precipio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.0 million, up 29.8% from fiscal 2024.
Precipio, Inc. (PRPO) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PRPO traded at $21.38, a market capitalization of $40.4 million.
Return on equity was −2.72% and debt-to-equity 0.07.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −2.40 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.